Skip to content

Author

K. S. Kidirniyazova

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Real-world outcomes of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma: A retrospective cohort study

Introduction . Hepatocellular carcinoma (HCC) ranks sixth in morbidity and third in mortality among oncological diseases in the world. The combination of atezolizumab (a PD-L1 inhibitor) and bevacizumab (anti-VEGF) is the standard of first-line systemic therapy for unresectable HCC based on the results of the random...

I. A. Filippov, E. A. Gaisina, M. S. Shvedsky et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.